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ABSTRACT
Introduction: Regulatory requirements mandate
that new drugs for treatment of patients with
type 2 diabetes mellitus (T2DM), such as
dipeptidyl peptidase-4 (DPP-4) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor
agonists, are evaluated to show that they do
not increase cardiovascular (CV) risk.
Methods: A systematic review was undertaken
to evaluate the association between DPP-4
inhibitor and GLP-1 receptor agonist use and
major adverse cardiac events (MACE). The
National Institutes of Health Medline database
was searched for pooled analyses,
meta-analyses, and randomized controlled
trials (RCTs) of DPP-4 inhibitors and GLP-1
receptor agonists that included CV endpoints.
Results: Thirty-six articles met the inclusion
criteria encompassing 11 pooled analyses, 17
meta-analyses, and eight RCTs (including
secondary analyses). Over the short term (up
to 4 years), patients with T2DM exposed to a
DPP-4 inhibitor or GLP-1 receptor agonist were
not at increased risk for MACE (or its
component endpoints) compared with those
who received comparator agents. Two
meta-analyses showed a significant reduction
in the incidence of MACE associated with DPP-4
inhibitor therapy as a drug class, but this
beneficial effect was not observed in other
meta-analyses that included large RCT CV
outcome studies. In four RCTs that evaluated
alogliptin, saxagliptin, sitagliptin, or
lixisenatide, there was no overall increased risk
for MACE relative to placebo in T2DM patients
at high risk for CV events or with established
CV disease, although there was an increased
rate of hospitalization for heart failure
associated with saxagliptin. A fifth RCT
showed that liraglutide reduced MACE risk by
13% versus placebo.
Conclusion: Overall, incretin therapy does not
appear to increase risk for MACE in the short
term.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) significantly
increases risk for cardiovascular (CV) disease [1].
Strategies for the management of CV risk factors
are therefore essential to reduce CV morbidity
and mortality associated with T2DM [1, 2].
While clinical trials have provided some
evidence that intensive glucose control in
patients with T2DM may reduce risk for
myocardial infarction (MI) and other major
adverse cardiac events (MACE), this is not the
case for all-cause mortality [3, 4]. The attendant
heightened risk for severe hypoglycemia with
intensive glucose-lowering treatment has been
postulated to be a significant counterbalance to
CV benefit [5]. Indeed, hypoglycemia and other
undesired adverse events (AEs) associated with
glucose-lowering drugs may be especially
deleterious in older, more frail patients with
multiple comorbidities [4]. Therefore, while
stringent glycated hemoglobin (HbA1c) targets
may be appropriate in some patients with
T2DM, comprehensive care is increasingly
regarded as requiring an individualized
approach that includes treatment of all CV
risk factors, not just hyperglycemia [1]. Drugs
with a good tolerability profile that do not
induce hypoglycemia may be compatible with
strict glycemic targets even in frail patients.
The two classes of incretin-based therapies,
dipeptidyl peptidase-4 (DPP-4) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor
agonists, can achieve reductions in HbA1c
without substantive risk for hypoglycemia [1].
As the use of these drugs in the management of
T2DM has increased [1], so too has interest in
their potential capacity to modify CV risk,
either detrimentally or beneficially.
Following concerns over the cardiac safety of
rosiglitazone and other antidiabetic drugs in
2008 [6], current regulatory guidance now
requires that new drugs for the treatment of
patients with T2DM must withstand long-term
and large-scale assessment of CV safety [7]. The
United States Food and Drug Administration
(US FDA) may approve an antidiabetic agent if
integrated analysis of completed studies
demonstrates that its upper 95% confidence
interval (CI) limit for the estimated risk ratio
(RR) for MACE is less than 1.3 versus
comparator. If, however, the upper bound is
between 1.3 and 1.8, sponsors must
subsequently demonstrate CV safety in
post-marketing CV outcomes trials [7].
Preclinical data and mechanistic studies of
DPP-4 inhibitors suggest possible additional
nonglycemic beneficial actions on blood
vessels and the heart, via both
GLP-1-dependent and GLP-1-independent
effects [8, 9]. Positive effects of DPP-4
inhibitors on the myocardium have also been
described in patients with ischemic heart
disease [8]. In patients with T2DM, DPP-4
inhibitors may improve total cholesterol and
triglyceride levels [10], reduce inflammatory
markers, oxidative stress, and platelet
aggregation, improve endothelial function
[8, 9], and increase circulating endothelial
progenitor cells possibly promoting vascular
repair [11]. In addition, DPP-4 inhibitors are
weight neutral [8].
Likewise, GLP-1 receptor agonists exert
pleiotropic effects on the CV system beyond
glycemic control. Overall, GLP-1 receptor
agonists have a beneficial effect on traditional
CV risk factors [12], and reduce body weight in
overweight or obese patients [13, 14].
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Treatment with GLP-1 receptor agonists in
patients with T2DM is associated with a
reduction in blood pressure, which precedes
weight loss [15]. Furthermore, longer-term
studies have also reported some improvements
in lipid profile [16], which could be the
consequence of body weight reduction. It has
been suggested that the direct stimulation of
GLP-1 receptors in the vasculature and
myocardium could produce further benefits on
CV risk [17]. Conversely, some clinical trial data
indicate that treatment with GLP-1 receptor
agonists can produce a modest increase in heart
rate [18], which may potentially be associated
with a higher CV risk [19].
By conducting a systematic literature review
of integrated analyses and randomized
controlled studies specifically designed to
assess MACE, we have further examined the
relationship between incretin therapies and CV
risk in patients with T2DM.
METHODS
This systematic review is reported in line with
the criteria stipulated in the PRISMA statement
[20]. To identify published clinical data on the
CV safety of incretin-based therapies in T2DM,
we conducted searches of the US National
Library of Medicine National Institutes of
Health Medline database as of the June 21,
2016.
First, we searched for meta-analyses of
randomized controlled trials of DPP-4
inhibitors and GLP-1 receptor agonists that
reported CV events, and pooled analyses of
patient-level data from randomized controlled
trials of individual DPP-4 inhibitors and GLP-1
receptor agonists that reported CV events.
Delimited by English language, the search
terms and Boolean strategy were as follows:
((alogliptin OR linagliptin OR saxagliptin OR
sitagliptin OR vildagliptin OR ‘‘dipeptidyl
peptidase-4 inhibitors’’ OR ‘‘DPP-4 inhibitors’’
OR gliptins) OR (exenatide OR liraglutide OR
albiglutide OR taspoglutide OR dulaglutide OR
lixisenatide OR semaglutide OR ‘‘glucagon-like
peptide-1 receptor agonists’’ OR GLP-1)) AND
cardiovascular AND (‘‘pooled analysis’’ OR
‘‘comprehensive analysis’’ OR ‘‘meta-analysis’’
OR ‘‘integrated analysis’’ OR ‘‘systematic review’’
OR ‘‘systematic assessment’’ OR ‘‘indirect
comparison’’). The authors screened the title
and abstract of each retrieved article for
relevance following which full-text articles
were obtained and reviewed qualitatively for
final inclusion and assessment. Articles solely
reporting data on surrogate CV endpoints (e.g.,
plasma lipids and blood pressure) were
excluded. Articles reporting analyses with
significant overlap (e.g., updated meta-analyses
including the same randomized controlled
trials) were excluded. In the case of overlap,
the paper reporting the largest dataset was
included. For the purpose of this review, a
pooled analysis was defined as analysis of
combined study data without weighting (i.e.,
as if the data were derived from a single sample)
and a meta-analysis was defined as an analysis
of combined study data after data from each
study had undergone weighting.
Second, we searched for randomized
controlled trials using Boolean logic and the
aforementioned drug terms combined with the
term ‘‘cardiovascular’’ and the terms
‘‘randomized OR randomised OR randomly’’.
Returned articles were reviewed qualitatively.
To qualify for inclusion, only randomized
controlled trials reporting CV outcomes as the
primary endpoint were selected. Duplicate
articles (i.e., articles reporting the same trial)
were excluded.
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This systematic review was undertaken to
assess the effects of DPP-4 inhibitors and GLP-1
receptor agonists on MACE with emphasis on
MI, stroke, CV death, and hospitalizations for
acute coronary syndromes (ACS) and heart
failure (HF) (or ACS and HF reported as severe
AEs). For each analysis, the total number of
MACE reported for individual incretins and
comparator therapy is reported, from which
exposure-adjusted incidence rates per
100 patient-years have been compiled. Our
primary objective was to report on the
base-case RR of patients having a CV-related
event whilst receiving a DPP-4 inhibitor or
GLP-1 receptor agonist versus all comparator
therapies. The RR estimates calculated by use of
other statistical methods and via sensitivity
analyses are reported on an individual
study-by-study basis, as they complement
base-case analyses. Time to MACE represents
an additional level of safety data and is reported
when possible. A secondary objective of our
review was to explore via subgroup analysis the
possibility that various factors influence MACE
RR. Finally, to identify possible reasons for
discrepancies in results between the integrated
analyses and CV outcome studies, extracted
baseline patient data for relevant articles have
been compared.
This article is based on previously conducted
studies, and does not involve any new studies of




Regarding meta-analyses of trial-level data and
pooled analyses of patient-level data, searches
yielded 109 articles, consisting of 74 articles
concerning DPP-4 inhibitors and 36 articles
concerning GLP-1 receptor agonists (one
meta-analysis of trial-level incretin therapy
data was identified in both searches) (Fig. 1a).
On the basis of the article abstracts, 71 articles
were dismissed primarily because an integrated
analysis of randomized controlled trial data or
CV endpoint data was not reported. Thus, 38
full-text articles were retrieved and further
reviewed for eligibility (Table 1), after which
28 articles met inclusion criteria and were
assessed further (Table 2).
Eight of 142 citations were identified in
relation to randomized controlled trials
reporting CV outcomes as a primary endpoint,
four of which concerned DPP-4 inhibitors and
one which concerned a GLP-1 receptor agonist
(Fig. 1b).
CV Risk of DPP-4 Inhibitors
Pooled Analyses
Features Of 11 pooled analyses of individual
gliptins that were assessed for eligibility, six
were assessed further, including two analyses of
linagliptin [21, 22], and one each for sitagliptin
[23], saxagliptin [24], vildagliptin [25], and
alogliptin [26]. Numbers, incidences, and RRs
of MACE associated with linagliptin and
sitagliptin were compared versus placebo,
active comparators, and placebo and active
comparators combined [21–23], whereas the
CV safety profiles of saxagliptin, vildagliptin,
and alogliptin were evaluated relative to all
comparators combined only [24–26]. One study
by Lehrke et al. of linagliptin versus placebo
included patient-level data pertaining to CV AEs
that were matched with respect to background
therapy [22], whereas the other studies
evaluated the MACE profile of DPP-4
inhibitors versus control without regard for
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concomitant antidiabetic background therapy
[21, 23–26].
Sample size was largest for the pooled
analysis of vildagliptin CV safety (n = 17,446)
and lowest for the pooled analysis of alogliptin
CV safety (n = 6028) (Table 3). Average
follow-up time was less than 2 years across all
analyses. Although the definitions of MACE
utilized in the saxagliptin, linagliptin,
vildagliptin, and alogliptin pooled analyses of
composite endpoints did vary, they were
broadly similar, encompassing CV death, MI,
ACS, and stroke. The linagliptin pooled analysis
of MACE by Rosenstock et al. was the only
analysis to include hospitalization for
unstable angina pectoris (UAP) in the
composite endpoint [21], while the saxagliptin
pooled analysis included ischemic events as an
additional MACE component [24]. The
examination of MACE and CV death in two
pooled analyses of linagliptin and alogliptin
were prespecified [21, 26], whereas these
endpoints were evaluated post hoc for the
other DPP-4 inhibitor analyses (Table 2),
which potentially introduces bias and reduces
the reliability of the data. The pooled analysis of
sitagliptin was further limited in that it
included a very broad MACE composite
Fig. 1 Individual ﬂow diagrams of included studies. Search
#1 = alogliptin OR linagliptinOR saxagliptin OR sitagliptin
OR vildagliptin OR ‘‘dipeptidyl peptidase-4 inhibitors’’ OR
‘‘DPP-4 inhibitors’’ OR gliptins; Search #2 = ‘‘pooled
analysis’’ OR ‘‘comprehensive analysis’’ OR ‘‘meta-analysis’’
OR ‘‘integrated analysis’’ OR ‘‘systematic review’’ OR
‘‘systematic assessment’’ OR ‘‘indirect comparison’’; Search
#3= cardiovascular; Search #4= exenatide OR liraglutide
OR albiglutide OR taspoglutide OR dulaglutide OR
lixisenatide OR semaglutide OR ‘‘glucagon-like peptide-1
receptor agonists’’ OR GLP-1; Search #5= randomized OR
randomised OR randomly; Search #6= cardiovascular or
heart [ﬁeld: Title/abstract]. *Included one pairwise and
network meta-analysis. CV cardiovascular, DPP-4 dipeptidyl
peptidase-4, GLP-1 glucagon-like peptide-1, RCTs
randomized controlled trials, T2DM type 2 diabetes mellitus
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Table 1 Search results: pooled analyses of patient-level data and meta-analyses of trial-level data from studies investigating
DPP-4 inhibitors and GLP-1 receptor agonists
First author, year
of publication
References Drug(s) assessed Publication type Met inclusion
criteriaa
DPP-4 inhibitors
Abbas, 2016 [42] Alogliptin, saxagliptin, and
sitagliptin
Meta-analysis Yes
Agarwal, 2014 [33] Allb Meta-analysis Yes
Cobble, 2012 [66] Saxagliptin Narrative review No
Engel, 2013 [23] Sitagliptin Pooled analysis Yes
Frederich, 2010 [67] Saxagliptin Pooled analysis No
Iqbal, 2014 [24] Saxagliptin Pooled analysis Yes
Johansen, 2012 [68] Linagliptin Pooled analysis No
Kongwatcharapong, 2016 [38] Allb Meta-analysis Yes
Kundu, 2016 [39] Alogliptin, sitagliptin, and
saxagliptin
Meta-analysis Yes
Lehrke, 2014 [22] Linagliptin Pooled analysis Yes
Li, 2016 [40] Allb Meta-analysis Yes
McInnes, 2015 [25] Vildagliptin Pooled analysis Yes
Monami, 2011 [69] Allb Meta-analysis No
Monami, 2012 [10] Allb Meta-analysis No
Monami, 2013 [29] Allb Meta-analysis Yes
Monami, 2014 [34] Allb Meta-analysis Yes
Patil, 2012 [30] Allb Meta-analysis Yes
Rosenstock, 2015 [21] Linagliptin Pooled analysis Yes
Savarese, 2015 [36] Allb Meta-analysis Yes
Schweizer, 2010 [64] Vildagliptin Pooled analysis No
Udell, 2015 [37] Alogliptin and saxagliptin Meta-analysis Yes
von Eynatten, 2013 [70] Linagliptin Pooled analysis No
Wang, 2016 [41] Allb Meta-analysis Yes
White, 2013 [26] Alogliptin Pooled analysis Yes
Williams-Herman, 2010 [71] Sitagliptin Pooled analysis No
Wu, 2013 [31] Allb Meta-analysis Yes
Wu, 2014 [35] Allb Meta-analysis Yes
Zhang, 2014 [32] Allb Meta-analysis Yesc
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(comprising 39 MedDRA terms), which as a CV
endpoint may be criticized because of its
heterogeneous definition and combination of
both safety and effectiveness endpoints [27],
and did not feature an independent process to
adjudicate instances of MACE [23]. Likewise,
the linagliptin post hoc pooled analysis by
Lehrke et al. assessed CV AEs based on
MedDRA terms [22]. The time span over which
a MACE or CV AE occurred in relation to drug
exposure ranged from 22 weeks to 59 weeks
across the six pooled analyses (Table 2).
MACE Incidence Rates Variable definitions
for MACE only allow exposure-adjusted
incidence rates to be compared within and not
between pooled analyses. Even so, Table 3
shows that exposure-adjusted incidence rates
of MACE were lower with every DPP-4 inhibitor
than with comparator regimens. Of the four
pooled analyses that reported MACE as a robust
endpoint [21, 24–26], exposure-adjusted
incidence rates ranged from 0.64 to 1.34
events per 100 patient-years for DPP-4
inhibitors (alogliptin, saxagliptin, vildagliptin,
and linagliptin) and from 1.04 to 1.89 events
per 100 patient-years for the competitors,
suggesting that treatment with DPP-4
inhibitors may reduce MACE in patients with




References Drug(s) assessed Publication type Met inclusion
criteriaa
GLP-1 receptor agonists
Ferdinand, 2016 [54] Dulaglutide Pooled analysis Yes
Fisher, 2015 [53] Albiglutide Pooled analysis Yes
Li, 2016 [56] Alld Meta-analysis Yes
Marso, 2011 [50] Liraglutide Pooled analysis Yes
Monami, 2009 [72] Alld Meta-analysis No
Monami, 2011 [73] Alld Meta-analysis No
Monami, 2013 [12] Alld Meta-analysis Yes
Ratner, 2011 [51] Exenatide Pooled analysis Yes
Seshasai, 2015 [52] Taspoglutide Pooled analysis Yes
Sun, 2012 [55] Alld Pairwise and network
meta-analysis
Yes




a Pooled analyses and meta-analyses meeting inclusion criteria were those that reported CV events as a primary objective.
All excluded papers were rejected on the basis that CV events were not explicitly reported (including papers containing no
analysis of adverse events), or were rendered redundant because of updated analyses
b Alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin ± dutogliptin
c Described CV events in general, which included MACE
d Exenatide, liraglutide, albiglutide, taspoglutide, dulaglutide, lixisenatide ± semaglutide
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Table 2 Study-level features of the integrated analyses describing the CV safety of DPP-4 inhibitors and GLP-1 receptor
agonists trialled in randomized controlled studies











Abbas, 2016 [42] Alogliptin
6.25–25 mg/daya; sitagliptin
100 mg/dayb; saxagliptin 2.5–5 mg/dayc
3 – 130d Post hoc
Engel, 2013 [23]e Sitagliptin (100 mg/day) 25 12 34 Post hoc




Kundu, 2016 [39] Alogliptin 6.25–25 mg/daya; sitagliptin
100 mg/dayb; saxagliptin 2.5–5 mg/dayc
3 – – Post hoc
Lehrke, 2014 [22] Linagliptin 5 mg/dayh 22 \2i 22 Post hoc
McInnes, 2015 [25] Vildagliptin (50 mg od and bd) 37 12 50.3 versus
48.7j
Post hoc
Rosenstock, 2015 [21] Linagliptin (C5 mg/day) 19 12 35 Prespeciﬁed
White, 2013 [26]k Alogliptin (C12.5 mg/day) 11 12 29 Prespeciﬁed
Udell, 2015 [37] Alogliptin 6.25–25 mg/daya; saxagliptin
2.5–5 mg/dayc
2 – 93 Post hoc
Agarwal, 2014 [33] DPP-4 inhibitors 82 24 44 Post hoc
Kongwatcharapong,
2016 [38]
DPP-4 inhibitors 54 12 59 Post hoc
Li, 2016 [40] DPP-4 inhibitors 43 12 61 Post hoc
Monami, 2013 [29] DPP-4 inhibitors 63 24 46 Post hoc
Monami, 2014 [34] DPP-4 inhibitors 82 24 47 Post hoc
Patil, 2012 [30] DPP-4 inhibitors 18 24 52 Post hoc
Savarese, 2015 [36] DPP-4 inhibitors 94 12 29d Post hoc
Wang, 2016 [41] DPP-4 inhibitors 68 24 24–52l Post hoc
Wu, 2013 [31] DPP-4 inhibitors 8 18 43 Post hoc
Wu, 2014 [35] DPP-4 inhibitors 50 24 45 Post hoc
Zhang, 2014 [32] DPP-4 inhibitors 12 18 NR Post hoc
Fisher, 2015 [53] Albiglutide (15–50 mg/week or 30 mg
biweekly)
9 16 104 Prespeciﬁed
8 Adv Ther (2017) 34:1–40
remain too small for reliable statistical analysis.
Exposure-adjusted incidence rate of MACE was
highest in both arms of the linagliptin analysis
conducted by Rosenstock et al. and it is
noteworthy that, beyond MI, the additional
term of hospitalization for UAP was a significant
contributor to this metric (0.49 per
100 patient-years for linagliptin and 0.48 per
100 patient-years for all comparators) [21]. A
high exposure-adjusted incidence rate of MACE
was also noticeable in the vildagliptin 50 mg
once and twice daily pooled analysis (0.90 per
100 patient-years for vildagliptin and 1.16 per
100 patient-years for all comparators), with
nonfatal MI the largest single contributor
(0.41 per 100 patient-years versus 0.48
per 100 patient-years, respectively) [25].
Exposure-adjusted CV death ranged from 0.24
to 0.34 per 100 patient-years for linagliptin [21],
sitagliptin [23], alogliptin [26], saxagliptin [24],
and vildagliptin [25].
MACE Risk Across the various pooled
analyses, none of the DPP-4 inhibitor
Table 2 continued











Ferdinand, 2016 [54] Dulaglutide (0.1–1.5 mg/week) 9 12 45 Prespeciﬁed
Ratner, 2011 [51] Exenatide (2.5, 5, and 10 lg bd) 12 12 23 Post hoc
Marso, 2011 [50]m Liraglutide (0.045–3.0 mg/day) 15 26 NR Post hoc
Seshasai, 2015 [52] Taspoglutide 20 mg/week 9 24 52 Prespeciﬁed
Li, 2016 [56] GLP-1 receptor agonists 21 16 78 Post hoc
Monami, 2013 [12] GLP-1 receptor agonists 25 24 42 Post hoc
Sun, 2012 [55] GLP-1 receptor agonists 45 8 27 Post hoc
Wang, 2016 [41]m Albiglutide, dulaglutide, exenatide,
liraglutide, lixisenatide
35 24 24–156 l Post hoc
bd twice daily, od once daily, NR not reported
a 25 mg in patients with an estimated glomerular ﬁltration rate (eGFR) of C60 mL/min/1.73 m2 of body surface area;
12.5 mg in patients with an eGFR of 30 to\60 mL/min/1.73 m2; and 6.25 mg in patients with an eGFR of\30 mL/min/
1.73 m2 [28]
b Or 50 mg daily if the baseline eGFR was C30 and\50 mL/min/1.73 m2 [44]
c 2.5 mg daily in patients with an eGFR B 50 mL/min/1.73 m2 [43]
d Median
e Did not include data from TECOS [44]
f Did not include data from SAVOR-TIMI 53 [43]
g 20, 40, or 100 mg/day was administered in one phase 2b study
h One of the 22 studies tested linagliptin 2.5 mg/day
i Nearly two-thirds of patients received treatment for at least 24 weeks [22]
j Mean duration of exposure for vildagliptin versus comparators [25]
k Did not include data from EXAMINE [28]
l Range of medians for studies of each DPP-4 inhibitor or GLP-1 receptor agonist
m Did not include data from LEADER [57]
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treatments were associated with an increased
risk for MACE relative to the respective control
group (95% CI limits spanned unity; Fig. 2a).
The upper 95% CI in the alogliptin pooled
analysis breached the US FDA mandated
threshold of 1.3, but findings from a
subsequent randomized, placebo-controlled
CV outcome trial demonstrated that the upper
boundary of a one-sided repeated CI for a
primary endpoint event was 1.16 (P\0.001 for
noninferiority, see below) [28]. Similar results to
the base-case pooled analyses were obtained for
linagliptin and sitagliptin when their data were
reanalyzed using different statistical techniques
[21, 23]. A time-to-event pooled analysis for
linagliptin revealed that the incidence of the
MACE increased over time as expected but at a
similar rate as that observed in the placebo
group [21]. Although theoretically possible that
differences in MACE between DPP-4 inhibitors
and controls are because of detrimental effects
of the active comparators, rather than of a
beneficial action of DPP-4 inhibitors, subgroup
analyses revealed that the CV safety of
linagliptin and sitagliptin compare favorably
with placebo [21, 23]. In the comparison of
linagliptin with placebo, the exposure-adjusted
incidence rates for MACE were 1.49 and 1.64
per 100 patient-years, respectively, yielding an
overall hazard ratio (HR) of 1.09 (95% CI
0.68–1.75) [21], while the corresponding rates
for sitagliptin versus placebo were 0.80 and 0.76
per 100 patient-years, respectively (incidence
rate ratio 1.01; 95% CI 0.55–1.86) [23].
Subgroup analyses further showed that the
magnitude of the adjudicated MACE risk
associated with linagliptin and vildagliptin
50 mg once and twice daily versus total
comparators was not affected by age, sex, or
high CV disease risk status [21, 25]. Race, use of
rescue therapy, occurrence of hypoglycemia,
renal function, microalbuminuria, or use of
background medication (insulin and/or
metformin) were also factors deemed not to
impact the magnitude of adjudicated MACE risk
associated with linagliptin versus total
comparators [21]. Subgroup analyses of
adjudicated MACE for saxagliptin suggested
that the 2.5 mg daily dosage regimen
(incidence rate ratio 0.33; 95% CI 0.10–0.89)
but not the 5 mg daily dosage regimen
(incidence rate ratio 0.74; 95% CI 0.40–1.36)
had a lower MACE risk relative to all
comparators [24]. Any saxagliptin dosage
adjunctive to metformin was not associated
with increased risk for MACE relative to control
(incidence rate ratio 0.93; 95% CI 0.44–1.99)
[24]. Limited data from three studies showed
that sitagliptin was associated with a lower
incidence and risk of MACE than a
sulfonylurea (exposure-adjusted incidence rate
0.00 per 100 patient-years with sitagliptin
versus 0.86 with sulfonylurea: incidence rate
ratio 0.00; 95% CI 0.00–0.31) [23].
MACE Components Although risks for
individual components of the composite
MACE endpoints were not consistently
reported across the pooled analyses, it was
apparent that the risks for individual CV
components were not increased with
Fig. 2 Risk of a MACE: a pooled analyses of patient-level
data for speciﬁc DPP-4 inhibitors, b meta-analyses of
trial-level data for speciﬁc DPP-4 inhibitors, and
c meta-analyses of trial-level data for DPP-4 inhibitors as
a drug class. MACEs were deﬁned differently in each
analysis (see Table 2). CI conﬁdence interval, DPP-4
dipeptidyl peptidase-4, HR hazard ratio, OR odds ratio, RR
risk ratio. aVildagliptin 50 mg once daily and twice daily.
bAll included studies. The principal analysis excluded seven
studies that did not report events. cUpper 95% CI not
shown. dDPP-4 inhibitor monotherapy versus metformin
monotherapy. eDPP-4 inhibitor plus metformin versus
metformin monotherapy. fDPP-4 inhibitors versus
sulfonylureas
c
16 Adv Ther (2017) 34:1–40
linagliptin, saxagliptin, or vildagliptin versus
total comparators [21, 24, 25], and that the risk
for CV-related death was not heightened by
sitagliptin relative to control (Table 4) [23].
There was some evidence suggesting that
linagliptin was associated with a reduced risk
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for stroke (incidence rate ratio 0.34; 95% CI
0.15–0.75) but this observation is based on a
low number of events, with many trials having
no events in one or both treatment groups. The
same caveat applies to the observation that
linagliptin may reduce risk for transient
ischemic attacks (Table 4).
One of the two linagliptin pooled analyses
assessed hospitalization for adjudicated
congestive HF (CHF) (from eight trials
including 3314 subjects) as well as
investigator-reported AEs suggestive of CHF
(from 24 placebo-controlled trials including
8778 subjects) [21]. Occurrence of
hospitalization for CHF was low for linagliptin
(12 events, 2039 patients) and the total
comparator group (nine events, 1275 patients)
yielding an HR of 1.04 (95% CI 0.43–2.47).
Occurrence of investigator-reported AEs
suggestive of CHF was also low for
linagliptin-treated patients (26 events, 0.5%;
16 serious events, 0.3%) and comparable with
that in placebo-treated patients (eight events,
0.2%; six serious events, 0.2%) [21]. In the other
linagliptin pooled analysis, rates of HF AEs
based on the preferred terms cardiac failure,
cardiac failure acute, and cardiac failure
congestive were similar among linagliptin- and
placebo-treated patients (0.2% and 0.3%,
respectively), equating to an incidence rate per
100 patient-years of 0.045 for linagliptin and
0.046 for placebo (Table 3) [22]. The large
vildagliptin pooled analysis indicated that this
agent is not associated with an increased risk of
HF defined as new onset or hospitalization for
worsening HF (RR 1.08; 95% CI 0.68–1.70;
Table 4) [25].
Meta-analyses
Features Of 20 articles identified from our
literature search on gliptins that met eligibility
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Ten reportedon theCVsafety ofDPP-4 inhibitors
as a drug class [29–36, 38, 40], seven reported on
the CV safety of individual DPP-4 inhibitors
[29, 30, 33, 34, 36, 38, 41], and three reported on
CV outcomes with alogliptin, sitagliptin and
saxagliptin or alogliptin and saxagliptin
combined [37, 39, 42] based on data pooled
from phase 4 studies—EXAMINE [28],
SAVOR–TIMI 53 [43], and TECOS [44]. Similar
robust definitions of MACE were applied in four
of the meta-analyses [29–31, 33], and a fifth
utilized an unclear definition of CV events rather
than MACE per se [32] (Table 3). Eight
meta-analyses focused on individual MACEs as
co-primary endpoints as opposed to a composite
MACE endpoint [33–36, 38–41].
Of the two meta-analyses that described
overall CV safety of individual DPP-4
inhibitors as a primary endpoint [29, 30], one
was restricted to monotherapy studies of 18
trials [30], whereas the other was extended to
studies in which DPP-4 inhibitors were
administered in association with other
glucose-lowering agents, provided that
concurrent therapies were the same in all
treatment groups [29]. All of the studies
included in the monotherapy analysis [30]
were also included in the larger analysis of all
available studies [29].
MACE Risk The larger of the two
meta-analyses assessing overall CV safety of
individual DPP-4 inhibitors included 70 trials:
nine trials of linagliptin, 13 trials of saxagliptin,
27 trials of sitagliptin, 16 trials of vildagliptin,
and five trials of alogliptin [29]. Sixty-three of
these 70 trials reported MACE, and enrolled a
total of 40,071 patients, including 23,562
assigned to treatment with one of the five
DPP-4 inhibitors and 16,509 assigned to
control treatment [29]. With a total of 263
MACE attributed to DPP-4 inhibitors, the
exposure-adjusted incidence rate of 1.12
events per 100 patient-years was not dissimilar
to that of the patient-level data in the
aforementioned pooled analyses (Table 3).
Overall, the results of this meta-analysis were
in agreement with the pooled analyses in that
no DPP-4 inhibitor was associated with a
statistically significant increased risk for MACE
as their 95% CIs crossed unity (Fig. 2b) [29].
More specifically, there was a general trend of
the base-case point estimates towards a MACE
risk reduction in patients assigned to any of the
five DPP-4 inhibitors relative to control,
although these reductions only reached
statistical significance with saxagliptin and
vildagliptin (Fig. 2b) [29]. Corresponding
findings from the smaller meta-analysis of
DPP-4 inhibitor monotherapy studies were
similar in that there was no suggestion of
statistically significant increased risk for MACE
with DPP-4 inhibitors but a statistically
significantly reduced MACE risk was detected
with sitagliptin (Fig. 2b) [30]; however, the
latter finding has subsequently been refuted by
the TECOS randomized, placebo-controlled
study, which demonstrated that sitagliptin
neither increased nor decreased MACE risk (see
below) [44].
A third meta-analysis tested the association
between individual DPP-4 inhibitors and risk for
the composite MACE endpoint as a secondary
objective [33]. By including EXAMINE and
SAVOR–TIMI 53 [28, 43] this meta-analysis
was unevenly weighted since these phase 4
trials were characterized by very large sample
sizes and prolonged follow-up relative to the
other phase 2/3 trials included in the analysis
[33]. Furthermore, the clinical characteristics of
the patients who participated in EXAMINE and
SAVOR–TIMI 53 were considerably different
from the populations of the other included
trials (i.e., patients were at higher risk for
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MACE) [28, 43]. Even so, no statistically
significant increased risk for MACE was
detected with any DPP-4 inhibitor in this
meta-analysis (Fig. 2b), and the available data
suggested that linagliptin could be associated
with a reduced risk for MACE [33].
Two meta-analyses suggested a significant
reduction in the incidence of MACE associated
with DPP-4 inhibitor therapy as a drug class,
with an estimated odds ratio (OR) of 0.48 (95%
CI 0.31–0.75) for the meta-analysis of
monotherapy studies [30] and 0.71 (95% CI
0.59–0.86) for the larger meta-analysis of all
available studies (Fig. 2c) [29]. However, in the
meta-analysis conducted by Agarwal et al. this
statistical advantage in favor of DPP-4 inhibitor
therapy was annulled when EXAMINE and
SAVOR–TIMI 53 data were included (OR 0.95;
95% CI 0.86–1.04) [33]. No change in effect size
was observed when the ORs were recalculated
using a continuity correction to avoid
distortions because of the exclusion of trials
with zero events [29, 30], or by use of a random
effects model instead of a fixed effects model
[33]. Subgroup analysis of the meta-analysis of
monotherapy studies revealed that studies with
a duration of at least 52 weeks demonstrated a
lower risk for MACE with DPP-4 inhibitor
therapy than control (RR 0.37; 95% CI
0.21–0.63; P = 0.0003), which was not the case
in shorter-term studies (RR 0.78; 95% CI
0.38–1.60; P = 0.50) [30]. Meta-regression
revealed no influence of sex, diabetes
duration, or HbA1c level upon the pooled OR
for MACE in the meta-analysis by Agarwal et al.
[33].
In the larger meta-analysis performed by
Monami et al., risk of MACE with DPP-4
inhibitor therapy was 28% lower when
compared with placebo based on 38 studies
with at least one event (OR 0.72; 95% CI
0.56–0.92; P = 0.01) [29]. However, in the
meta-analysis restricted to monotherapy
studies, no such reduction in MACE risk was
observed for DPP-4 inhibitor therapy versus
placebo (RR 1.05; 95% CI 0.39–2.82; P = 0.92)
but there appeared to be a significantly lower
risk relative to metformin (RR 0.42; 95% CI
0.20–0.87; P = 0.02) and other oral
hypoglycemic agents, including sulfonylureas
and thiazolidinediones (RR 0.33; 95% CI
0.16–0.67; P = 0.002) [30]. A lower CV safety
risk with DPP-4 inhibitor therapy versus active
comparators was also observed in two other
meta-analyses (Fig. 2c) [31, 32]. One
meta-analysis indicated that DPP-4 inhibitor
monotherapy was associated with less risk for
MACE than metformin monotherapy (RR 0.36;
95% CI 0.15–0.85; P = 0.02), but that this safety
advantage was lost when metformin was added
to the DPP-4 inhibitor regimen as initial
combination therapy (RR 0.54; 95% CI
0.25–1.19; P = 0.13) [31]. The other
meta-analysis, which used a less robust MACE
definition, suggested that CV events were less
likely with DPP-4 inhibitor therapy than with
sulfonylurea therapy (OR 0.53; 95% CI
0.32–0.87) but that patients receiving DPP-4
inhibitor therapy were also slightly less likely to
attain HbA1c below 7% (OR 0.91; 95% CI
0.84–0.99) [32].
Fixed and random effects meta-analyses of
three phase 4 prospective CV outcome studies
found no evidence for an increased risk of
MACE associated with alogliptin, saxagliptin,
and sitagliptin as a class versus placebo in
high-risk patients with T2DM (fixed and
random effects model: RR 0.99; 95% CI
0.93–1.06 [42]; random effects model: OR 0.99;
95% CI 0.92–1.06 [39]). However, the scientific
validity of pooling clinical trial data from
distinct CV risk populations must be taken
into consideration when interpreting these
results.
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Twelve of the 14 meta-analyses reported
individual DPP-4 inhibitor data and DPP-4
inhibitor data as a drug class on the
components of MACE composite endpoints
[29, 30, 33–42]. In general, there was no class
effect on the risk for the three most commonly
used MACE components (CV death, MI, and
stroke), as well as for other MACE components
(Table 4). The drug class was associated with
lower risk for MI in two meta-analyses [29, 36],
although this association was lost over the long
term (i.e., more than 29 weeks’ treatment) in
the meta-analysis that included EXAMINE and
SAVOR-TIMI 53 data (see below) [36].
Ninety-five percent CIs of pooled ORs/RRs for
death, CV death, MI, and stroke included the
value 1 when the data were stratified by
individual DPP-4 inhibitor therapy, with the
exception of stroke risk with linagliptin (OR
0.45; 95% CI 0.23–0.89 [33]; RR 0.29; 95% CI
0.13–0.65; P = 0.003 [36]) and vildagliptin (OR
0.23; 95% CI 0.07–0.71 [33]; RR 0.30; 95% CI
0.10–0.92; P = 0.035 [36]; and OR 0.26; 95% CI
0.08–0.84 [41]). Vildagliptin was also associated
with significant reduction in the risk of MI (RR
0.35; 95% CI 0.17–0.72; P = 0.004) [36]. There
was a higher risk for HF associated with DPP-4
inhibitors as a drug class in a meta-analysis that
focused on this outcome as a primary endpoint
[34], as well as a 16% increased HF risk in two
other meta-analyses that included EXAMINE
(alogliptin) and SAVOR-TIMI 53 (saxagliptin)
data [35, 36]. A meta-analysis of EXAMINE and
SAVOR–TIMI 53 data exclusively indicated that
DPP-4 inhibitor therapy with either alogliptin
or saxagliptin was associated with a 25%
increased risk for HF relative to standard care
with glucose or weight management (RR 1.25;
95% CI 1.08–1.45; P = 0.0033) [37], although
this risk became nonsignificant in four other
meta-analyses also featuring TECOS data
(sitagliptin versus placebo) (RR 1.12; 95% CI
1.00–1.25 [42]; OR 1.14; 95% CI 0.97–1.34 [39];
RR 1.116; 95% CI 0.995–1.228 [38]; OR 0.97;
95% CI 0.61–1.56 [40]; Table 4). When analyzed
individually, only saxagliptin was associated
with increased risk for HF (RR 1.215; 95% CI
1.028–1.437; P = 0.022 [38]; OR 1.23; 95% CI
1.03–1.56 [41]), which is likely driven by an
increased risk in patients at high CV risk (RR
1.257; 95% CI 1.060–1.491; P = 0.009) rather
than low CV risk (RR 0.537; 95% CI
0.232–1.245; P = 0.148) [38].
Randomized Controlled Trial Data
We identified one primary article and one
secondary article for the Examination of
Cardiovascular Outcomes with Alogliptin
versus Standard of Care (EXAMINE) trial
[28, 45], one primary article and two
secondary articles for the Saxagliptin
Assessment of Vascular Outcomes Recorded in
Patients with Diabetes Mellitus
(SAVOR)–Thrombolysis in Myocardial
Infarction (TIMI) 53 (SAVOR-TIMI 53) trial
[43, 46, 47], and one primary article for the
Trial to Evaluate Cardiovascular Outcomes after
Treatment with Sitagliptin (TECOS) [44].
Overall, EXAMINE, SAVOR-TIMI 53, and
TECOS found no evidence that DPP-4
inhibitor therapy alters MACE risk relative to
placebo [28, 43, 44, 48].
EXAMINE was a double-blind, noninferiority
trial, wherein alogliptin as an adjunct to
standard care was compared with standard
care alone in 5380 patients with T2DM
comorbid with ACS [28]. Doses of alogliptin
were adjusted according to kidney function at
the time of randomization and when needed
during the trial on the basis of estimated
glomerular filtration rate (eGFR) calculated
with the use of the Modification of Diet in
Renal Disease formula. Inclusion criterion for
T2DM at screening was an HbA1c level of
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6.5–11.0% despite treatment with antidiabetic
therapy other than a DPP-4 inhibitor or GLP-1
receptor agonist. ACS must have occurred
within 15–90 days prior to randomization, and
was defined as acute MI and unstable angina
requiring hospitalization [49]. The primary
outcome was time from randomization to
occurrence of a MACE, which was defined as a
composite of CV death, nonfatal MI, or nonfatal
stroke. Baseline mean HbA1c level was 8.0% in
both groups. There was no statistically
significant difference between the two groups
for the primary endpoint (HR 0.96; 95%
CI B1.16%, P = 0.32; P\0.001 for
noninferiority), for components of the primary
endpoint, and for all prespecified secondary and
exploratory endpoints, including hospital
admission for HF (Table 5) [28, 45]. Post-hoc
analysis of EXAMINE indicated that risk of CV
death and hospital admission for HF was similar
for alogliptin and placebo, both in the entire
study population (HR 1.00; 0.82–1.21) and in
those with a history of HF at baseline (HR 0.90;
0.70–1.17) [45].
SAVOR-TIMI 53 compared renally adjusted
saxagliptin with placebo when added to
current therapy in 16,492 patients with
established T2DM (baseline mean HbA1c
level, 8.0%) who had a history of, or who
were at risk for, CV events [43]. Patients with
documented CV disease were at least 40 years
of age, and had a history of a clinical event
associated with atherosclerosis involving the
coronary, cerebrovascular, or peripheral
vascular system. Patients with multiple risk
factors for CV events were at least 55 years old
(men) or 60 years old (women) with at least
one of the following additional risk factors:
dyslipidemia, hypertension, or active smoking.
The primary outcome was time to first MACE,
defined as a composite of CV death, nonfatal
MI, or nonfatal ischemic stroke. Patients were
followed for a median of 2.1 years, during
which time their antidiabetic medications and
other medications could be adjusted at the
discretion of their attending physician. As in
EXAMINE, the SAVOR-TIMI 53 data revealed
no statistically significant difference between
the groups regarding the primary endpoint:
7.3% of patients in the saxagliptin arm and
7.2% of patients in the placebo arm
experienced a MACE (HR 1.00; 95% CI
0.89–1.12, P = 0.99; P\0.001 for
noninferiority) (Table 5). However, unlike
therapy with alogliptin in EXAMINE, therapy
with saxagliptin increased the relative risk of
hospitalization for HF (3.5% versus 2.8%; HR
1.27; 95% CI 1.07–1.51; P = 0.007)
corresponding to a 0.7% absolute risk over
2 years [43]. Incidence of hospitalization for
HF was also higher in the saxagliptin than
placebo group at 12 months (1.9% versus
1.3%; HR 1.46; 95% CI 1.15–1.88; P = 0.002)
[46]. Multivariable analyses revealed that
subjects at greatest risk of hospitalization for
HF had previous HF (adjusted HR 4.18; 95%
CI 3.48–5.02), an eGFR B60 mL/min (adjusted
HR 2.00; 95% CI 1.65–2.42), or elevated
baseline levels (quartile 4) of N-terminal pro
B-type natriuretic peptide (adjusted HR 5.51;
95% CI 4.24–7.16) [46]. Risk of MACE in
SAVOR-TIMI 53 was similar among elderly
(C65 years, HR 0.92; 95% CI 0.79–1.06;
\65 years, HR 1.15; 95% CI 0.96–1.37;
interaction P value 0.06) and very elderly
(C75 years, HR 0.95; 95% CI 0.75–1.22;
\75 years, HR 1.01; 95% CI 0.89–1.15;
interaction P value 0.67) patients who
received saxagliptin and placebo [47]. The
increased risk of HF-associated hospitalization
with saxagliptin relative to placebo was similar
regardless of age group [47].
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TECOS was a randomized, double-blind trial
that assigned 14,671 T2DM patients (baseline
mean HbA1c level, 7.2%) to either sitagliptin
100 mg daily (or 50 mg daily if baseline eGFR
was C30 and\50 mL/min/1.73 m2 of body
surface area) (n = 7257) or placebo (n = 7266) in
addition to their existing therapy (oneor twooral
hypoglycemic agents or insulin with or without
metformin) [44]. Open-label use of
antihyperglycemic therapy was encouraged as
required for the attainment of appropriate
glycemic targets. Eligible patients were at least
50 years of age and had established CV disease
defined as a history of major coronary artery
disease, ischemic cerebrovascular disease, or
atherosclerotic peripheral arterial disease. In
TECOS, MACE was defined as the composite of
CV death, nonfatal MI, nonfatal stroke, or
hospitalization for unstable angina. During a
median follow-up of 3.0 years (interquartile
range 2.3–3.8 years), sitagliptin was noninferior
to placebo with respect to MACE (HR 0.98; 95%
CI 0.88–1.09; P\0.001), and there was no
statistically significant between-group
difference regarding rates of hospitalization for
HF (HR 1.00; 95% CI 0.83–1.20; P = 0.98)
(Table 5) [44].
CV Risk of GLP-1 Receptor Agonists
Pooled Analyses
Features Of nine articles on GLP-1 receptor
agonists identified from our literature search,
five were drug-specific pooled analyses—one
each for liraglutide [50], exenatide twice daily
[51], taspoglutide [52], albiglutide [53], and
dulaglutide [54] (Table 2). Excluding
taspoglutide (since development has been
suspended), the sample size was largest for
the pooled analysis of liraglutide CV safety
(n = 6638) and smallest for that of exenatide
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CV safety of the drugs with or without
background therapy. CV safety was compared
with all active interventions combined for
liraglutide [50], with placebo and insulin
combined for exenatide [51], and with
placebo and active comparators combined for
albiglutide [53] and dulaglutide [54]. The
authors of the exenatide study acknowledge
that pooling the placebo group with a single
active-comparator group was a necessary
limitation to provide greater statistical power
[51]. Adjudicated MACEs were evaluated on a
post hoc basis in the liraglutide and exenatide
analyses but were prespecified in the
albiglutide and dulaglutide analyses
[50, 51, 53, 54]. The MACE definitions were
broadly similar except that the exenatide
pooled analysis included ACS and
revascularization procedures in addition to
CV death, stroke, and MI [51]. Technically,
time to first MACE was a secondary endpoint
in the albiglutide pooled analysis, as the
primary endpoint was time to first MACE or
hospital admission for UAP [53].
MACE Risk Point estimates suggest there is no
increased risk of MACE with liraglutide,
exenatide twice daily, albiglutide, and
dulaglutide relative to controls although their
associated 95% CIs were wide (Fig. 3)
[50, 51, 53]. While the RRs for adjudicated
MACE were less than 1.0 compared with
comparators, the upper 95% CI boundaries
were greater than 1.3 except for dulaglutide.
Importantly, the RRs and 95% CIs of MACE
associated with liraglutide and exenatide were
consistent across multiple analysis methods
whether it was use of expanded MACE terms
or alternative statistical techniques [50, 51]. The
upper boundaries of the 95% CIs for MACE HRs
Fig. 3 Risk of a CV event with GLP-1 receptor agonist
according to integrated analyses of patient- and trial-level
data. AEs adverse events, CI conﬁdence interval, CV
cardiovascular, GLP-1 glucagon-like peptide-1, HR hazard
ratio, MACE major adverse cardiac events, OR odds ratio,
RR risk ratio. aPrimary endpoint: MACE composite
endpoint or hospital admission for unstable angina [53].
bSecondary endpoint: MACE composite endpoint only
[53]. cSecondary MACE composite endpoint, which
included all relevant CV AEs [i.e., all terms of the primary
MACE endpoint plus terms for arrhythmia, heart failure
(with or without hospitalization), and mechanical-related
events] [51]
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associated with albiglutide exceeded 1.3
regardless of whether the control arm was all
comparators, placebo, or active comparators
[53].
Aside from a protective effect of dulaglutide
regarding nonfatal MI, there was no effect of
albiglutide and dulaglutide on the risk for
MACE components in the two pooled analyses
that reported such data (Table 4) [53, 54].
Meta-analyses
Features We identified four meta-analyses of
GLP-1 receptor agonists for assessment (Table 2)
[12, 41, 55, 56]. One meta-analysis of trial-level
data reported comparisons between GLP-1
receptor agonists and non-GLP-1 receptor
agonists [12]. Composite data were taken from
37 trials of which 33, 29, 29, 33, and 31 reported
on MACE, MI, stroke, all-cause mortality, and
CV mortality, respectively, and 25 reported at
least one event [12]. Most of the 37 trials
pertained to exenatide (n = 21 for exenatide
twice daily; n = 5 for exenatide once daily), with
eight trials of liraglutide, two of albiglutide, and
one of taspoglutide. These studies enrolled a
total of 15,398 patients at low risk for a MACE,
including 8619 assigned to treatment with a
GLP-1 receptor agonist and 6779 assigned to a
comparator (Table 3) [12]. The definition of
MACE was the same as that reported by
Monami et al. in a large meta-analysis of
DPP-4 inhibitor therapy [12, 29].
MACE Risk Similar to the findings of the
pooled analyses of liraglutide and exenatide
twice daily, the meta-analysis by Monami et al.
suggested no increased risk for MACE with
GLP-1 receptor agonists as a drug class relative
to all comparators (OR 0.78; 95% CI 0.54–1.13;
P = 0.18) (Fig. 3) [12]. Subgroup analysis found
that GLP-1 receptor agonists could be associated
with a significant reduction in the incidence of
MACE relative to placebo (OR 0.51; 95% CI
0.28–0.93; P = 0.029) and pioglitazone (OR
0.12; 95% CI 0.02–0.99; P = 0.049), but no
such benefit was observed relative to DPP-4
inhibitors, sulfonylureas, or insulin. No
significant effect of GLP-1 receptor agonists
was observed on any component of the MACE
endpoint (Table 4).
A second meta-analysis was a pairwise
analysis of 15,883 patients who participated in
45 randomized controlled trials [55]. It was
designed to reveal any significant differences
between GLP-1 receptor agonists and placebo,
active comparators, or another GLP-1 agent on
CV safety (i.e., CV mortality, ischemic heart
disease, nonfatal HF, and stroke). The incidence
of CV events with GLP-1 receptor agonists and
placebo was low [40/5826 (0.7%) and 28/2350
(1.2%), respectively], and no significant
association could be detected (OR 0.7; 95% CI
0.40–1.22; P = 0.2). Similarly, the incidences of
CV events for GLP-1 receptor agonists and
active comparators were low (0.9% and 0.7%,
respectively), yielding an OR of 1.06 (95% CI
0.65–1.74; P = 0.8). A network analysis, which
was conducted on the same dataset to support
the pairwise analysis and to supplement missing
evidence of direct comparisons of GLP-1
receptor agonists, found no statistically
significant difference in CV events between
any comparisons. Subgroup analysis of the
pairwise comparisons did not detect any
difference in CV events with respect to study
duration (less than 52 weeks versus 52 weeks or
longer) or individual GLP-1 receptor agonists
versus comparator [55].
Table 4 shows that the GLP-1 receptor
agonist drug class and its members were not
associated with increasing risk of MACE
components, including heart failure, on the
basis of results of three meta-analyses
[12, 41, 56], although there was evidence
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associating exenatide with increased risk of
arrhythmia (OR 2.83; 95% CI 1.06–7.57) [41].
Randomized Controlled Trial Data
We identified one primary article each for the
Evaluation of Lixisenatide in Acute Coronary
Syndrome (ELIXA) trial [48] and the Liraglutide
Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) trial
[57].
ELIXA was the first randomized,
double-blind, noninferiority trial to assess the
effects of a GLP-1 receptor agonist (lixisenatide)
versus placebo on CV outcomes in patients with
T2DM (baseline mean HbA1c level, 7.6%)
receiving locally determined standards of care
[48]. Participants of ELIXA had had an acute
coronary event (i.e., within 180 days before
screening), although not as recently as those
who took part in EXAMINE [28, 48]. A starting
lixisenatide dosage of 10 lg/day was
administered during the first 2 weeks and then
increased to a maximum dosage of 20 lg/day at
the investigator’s discretion [48]. Over a median
follow-up period of 25 months, lixisenatide was
noninferior to placebo regarding time to first
MACE (composite of CV death, nonfatal MI,
nonfatal stroke, or hospitalization for
unstable angina) as the upper boundary of the
95% CI of the HR was less than 1.3 (HR 1.02;
95% CI 0.89–1.17; P\0.001; Table 5).
Superiority of lixisenatide to placebo was also
not demonstrated since the upper boundary of
the 95% CI was not less than 1.0 (P = 0.81).
There was no statistical separation between the
groups with respect to rate of hospitalization for
HF (HR 0.96; 95% CI 0.75–1.23; P = 0.75 for
superiority) [48].
LEADER was a randomized, double-blind,
noninferiority trial of 9340 T2DM patients
who had a higher baseline HbA1c level than
the other CV outcome trials (mean, 8.7%) [57].
Patients were stratified by baseline eGFR status
(\30 or C30 mL/min/1.73 m2 of body surface
area) and assigned with equal probability to
treatment with either 1.8 mg (or the maximum
tolerated dose) of liraglutide (n = 4668) or
placebo (n = 4672) once daily as a
subcutaneous injection in addition to standard
care. Use of antihyperglycemic therapy was
permitted for the attainment of an HbA1c less
than 7.0%. Eligible patients were either
(1) 50 years of age or more with at least one
coexisting CV condition (coronary heart
disease, cerebrovascular disease, peripheral
vascular disease, chronic kidney disease of
stage C3, or chronic HF of New York
Heart Association class II or III); or (2) 60 years
of age or more with at least one CV risk factor
(microalbuminuria or proteinuria, hypertension
and left ventricular hypertrophy, left
ventricular systolic or diastolic dysfunction, or
an ankle–brachial index [the ratio of the systolic
blood pressure at the ankle to the systolic blood
pressure in the arm] of less than 0.9). In
LEADER, the primary composite outcome in
the survival analysis was the first occurrence of
death from CV causes, nonfatal (including
silent) MI, or nonfatal stroke. During a median
follow-up of 3.8 years, the primary MACE
outcome occurred in a lower proportion of
patients in the liraglutide group than in the
placebo group (13.0% versus 14.9%; HR 0.87;
95% CI 0.78–0.97; P\0.001 for noninferiority;
P = 0.01 for superiority; Table 5). There was no
difference between the groups regarding risk of
hospitalization for HF (HR 0.87; 95% CI
0.73–1.05; P = 0.14 for superiority).
CONCLUSIONS
CV risk is around twice as great in patients with
than without T2DM [58], with degree of risk
correlatingwithHbA1c level [59]. Consequently,
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achievement of tight glycemic control whilst
minimizing CV risk is an important treatment
objective in the management of T2DM [2]. This
aim is supported by 10-year follow-up data from
the United Kingdom Prospective Diabetes Study
(UKPDS), which highlight the importance of
intensive glycemic control not only for
reduction of microvascular endpoints but also
for emergent risk reduction for MI and death
from any cause [3]. Yet, other data have shown
limited benefits of intensive glycemic control on
all-cause mortality and CV deaths, with
hypoglycemia-associated harm outweighing
potential benefits [5, 20]. This discrepancy
might be explained by diabetes duration; the
findings of recent large-scale trials such as Action
to Control Cardiovascular Risk in Diabetes
(ACCORD), Action in Diabetes and Vascular
Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE), and
the Veterans Affairs Diabetes Trial are derived
from patient populations with T2DM of
moderate-to-long duration [4]. While trials with
less favorable CV outcomes have tended to be
those in which the risk of severe hypoglycemia
associated with treatment intensification is
greater [60], post hoc analysis of ACCORD data
indicate that it may be factors relating to a
persistent average HbA1c greater than 7% that
are associated with excessive all-cause mortality
rather than intensive glycemic control regimens
per se [61].
Our systematic literature review presents
findings supporting the premise that
short-term treatment of T2DM with DPP-4
inhibitors or GLP-1 receptor agonists is not
associated with an increased risk of MACE, and
on the contrary, that liraglutide reduces MACE
risk by 13% versus placebo in patients at high
risk for MACE. Indeed, an interesting finding
from the ELIXA and LEADER trials was the
potential for an inter-drug class difference on
MACE risk with respect to GLP-1 receptor
agonists: time to death from a MACE was
lower with liraglutide than with placebo in
LEADER, which was not the case with
lixisenatide versus placebo in ELIXA [48, 57].
Furthermore, since our June 21, 2016 search,
the Trial to Evaluate Cardiovascular and Other
Long-term Outcomes with Semaglutide in
Subjects with Type 2 Diabetes (SUSTAIN-6) has
been published [62]. The main finding of
SUSTAIN-6, which included 3297 patients at
high CV risk, was that semaglutide was
noninferior to placebo regarding rate of first
occurrence of MACE (HR 0.74; 95% CI
0.58–0.95; P\0.001 for noninferiority) [62].
The large-scale CV outcome trials were
conducted specifically to evaluate the safety
and efficacy of incretins versus placebo with
regard to CV outcomes in patients with T2DM
at high risk for CV events [28, 43, 48] or
established CV disease [44, 57]. Thus, they
differed fundamentally from most of those
included in the evaluated pooled analyses and
meta-analyses of incretins, which tended to
include patients at low risk for CV events.
Nevertheless, composite MACE data from the
CV outcome trials of alogliptin, saxagliptin,
sitagliptin, and liraglutide were generally in line
with the findings of the corresponding
drug-specific pooled analyses in that there was
no indication that the incretin was associated
with increasing CV risk over an approximate 2-
to 4-year follow-up period. Although observed
risk reductions were numerically greater in the
pooled analyses than in the respective
outcomes trials (e.g., the MACE RR point
estimates in the pooled analyses of saxagliptin
and sitagliptin were less than the lower limit of
the 95% CIs for MACE HRs in the
corresponding outcome trials), it should be
noted that patients enrolled in EXAMINE,
SAVOR-TIMI 53, TECOS, and LEADER had a
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longer duration of T2DM and were at higher
risk of CV disease. Furthermore, the CV
outcome studies assessed the performance of
alogliptin, saxagliptin, sitagliptin, and
liraglutide versus placebo whereas the pooled
analyses compared the CV safety of these agents
versus all comparator agents combined.
The only potential CV safety signal raised to
date is the increased rate of hospitalization for
HF associated with saxagliptin treatment in
SAVOR-TIMI 53 [43]. While no such finding
was detected in the pooled analysis of
saxagliptin trials (HR 0.55; 95% CI 0.27–1.12)
[24], three meta-analyses of DPP-4 inhibitors
did indicate that this drug class or certain
members of it may slightly increase risk for
HF. Of course, a major caveat would be that the
findings of the meta-analyses are heavily
influenced by inclusion of SAVOR-TIMI 53,
which was responsible for a large proportion
of the investigator-reported events [34–36].
There was no significantly increased risk for
HF reported for alogliptin in EXAMINE [63],
sitagliptin in TECOS [44], lixisenatide in ELIXA
[48], or liraglutide in LEADER [57]. It is possible
that a risk of HF associated with DPP-4
inhibitors is present in certain subpopulations
of patients, but this requires further
investigation.
Our systematic review has a number of
limitations that should be considered when
interpreting the findings. Methodologically,
pooled analyses of patient-level data are more
sensitive than meta-analyses of trial-level data
because the former contain a greater amount of
information (e.g., time to event) compared with
the latter, which only capture whether an event
has occurred during the evaluated trials. This
difference is particularly relevant when
considering longer-term trials, but can also
affect short-term studies, such as those
included in the present integrated analyses.
Furthermore, meta-analyses that exclude trials
with no reported events can produce further,
small distortions in overall event rates. Some of
the trials of individual DPP-4 inhibitors that are
indirectly captured in the present analysis did
not adequately report CV events and were
therefore excluded from two of the
meta-analyses [29, 30], while still included in
the pooled analyses of individual gliptins
[21, 24, 64]. The updated vildagliptin pooled
analysis [25] also included many more studies
(37 versus 16 studies) that did not feature in the
meta-analysis performed by Monami et al. [29].
When assessing data across individual pooled
analyses, it is important to bear in mind that
differences in event rates could arise from
diversities in case mix, definition and
adjudication of events, choice of comparators,
and methods of analysis, rather than differences
in the actual therapeutic effects across
molecules of the class. Finally, the extent of
publication bias in this systematic review is
likely minimal given that reporting MACE in
randomized controlled trials of new
antidiabetic agents is mandatory.
There are also several inherent study design
limitations to the CV outcome trials. Firstly,
study participants were followed for a
reasonably short period of time, and,
therefore, benefits and risks of longer-term
treatment with the various incretin therapies
with respect to CV outcomes requires further
determination. For instance, the benefit of
improved glycemic control in reducing the
risk of MI in UKPDS did not become
statistically significant until 10 years of
follow-up after the initial treatment period [3].
Secondly, in addition to DPP-4 inhibitor or
placebo, all study patients received
concomitant therapies as standard-of-care
treatment for T2DM and CV risk factors
(according to regional guidelines). While use
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of these therapies tended to be well balanced
between the treatment groups, there was a high
standard of care across the study populations.
This might have minimized potential
differences in CV event rates between
treatment groups, although most likely to a
lesser extent in EXAMINE because of the high
event rate in the post-ACS population. Thirdly,
at the end of the study periods, there was a
small change between the treatment groups in
HbA1c levels in favor of alogliptin versus
placebo (-0.36%; P\0.001), saxagliptin versus
placebo (-0.2%; P\0.0001), sitagliptin versus
placebo (-0.29%; P value not reported),
lixisenatide versus placebo (-0.27%;
P\0.001), and liraglutide versus placebo
(-0.40%; 95% CI -0.45 to -0.34)
[28, 43, 44, 48, 57]. However, none of the
studies were designed to detect a difference in
glycemic control between treatment arms, and
in SAVOR-TIMI 53, TECOS, and LEADER,
background glucose-lowering treatment was
intensified more in the placebo group than in
the active treatment groups [43, 44, 57]. Finally,
in EXAMINE and ELIXA [28, 48], patients were
treated with incretin therapy approximately
6 weeks and 10 weeks post-ACS, respectively,
and it is not known if initiating treatment
earlier than 1 month would have had beneficial
effects on CV outcomes.
Several other large-scale clinical trials
intended to assess CV outcomes associated
with incretin therapy in T2DM are ongoing.
The Cardiovascular Outcome Study of
Linagliptin versus Glimepiride in Patients with
Type 2 Diabetes (CAROLINA; Clinical-
Trials.gov, NCT01243424) trial is the first
head-to-head outcome trial of a DPP-4
inhibitor compared with an active comparator
that is powered to demonstrate differences in
CV events among patients with early T2DM and
increased CV risk or established complications
[65]. The primary outcome is time to first
occurrence of CV death, nonfatal MI, nonfatal
stroke, or hospitalization for UAP. Recruitment
into CAROLINA was completed in 2012 after
6041 patients were randomized and treated
with study drug [65]. The estimated
completion date is 2018. The CAROLINA trial
will be the first study to address the clinical
question of whether a DPP-4 inhibitor is a more
suitable second-line therapy than a sulfonylurea
for CV protection in T2DM.
The Cardiovascular and Renal Microvascular
Outcome Study with Linagliptin in Patients
with Type 2 Diabetes Mellitus at High Vascular
Risk (CARMELINA; ClinicalTrials.gov,
NCT01897532) is comparing the long-term
effect of linagliptin on CV outcomes versus
placebo and is the only ongoing outcome study
with a DPP-4 inhibitor that is powered for renal
microvascular outcomes and will assess renal
disease progression over time. The primary
endpoint is a composite of CV death, nonfatal
MI, nonfatal stroke, and hospitalization for
UAP. Patient enrollment began in July 2013
and final results are anticipated in 2017. There
is no ongoing CV outcome study of vildagliptin,
which is marketed ex-US only. Other CV
outcome trials in patients receiving GLP-1
receptor agonists include EXenatide Study of
Cardiovascular Event Lowering (EXSCEL;
exenatide once-weekly; expected completion
year, 2017), FREEDOM-CVO (exenatide
subcutaneous pump; completed but
unpublished), and Researching Cardiovascular
Events With a Weekly Incretin in Diabetes
(REWIND; dulaglutide weekly; expected
completion year, 2019).
In conclusion, integrated analyses of short-
and medium-term randomized trials along with
findings from large CV outcome trials indicate
that treatment of T2DM patients with incretin
therapy neither increases nor decreases risk for
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MACE, with the exception of liraglutide where
results of the LEADER study show a moderate
risk reduction in the occurrence of MACE in
T2DM patients with increased CV risk. Risk data
pertaining to some individual MACE
components derived from integrated analyses
and collected in large CV outcome trials of
DPP-4 inhibitors were equivocal (e.g., MI, ACS,
and HF). Ongoing clinical trials on CV
outcomes will help to verify these findings.
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